[Lung diseases during therapeutic aplasia: diagnostic and therapeutic strategy].
Lung diseases that occur in patients with drug-induced bone marrow aplasia are part of a wider group of lung diseases in immunocompromised patients. Their most common causes are infections due to Gram-negative bacilli, staphylococci or Aspergillus spp. and intra-alveolar haemorrhages. Their diagnostic approach is often limited by disorders of coagulation, risks of infection by bronchial or pulmonary seeding during endoscopy and the lethal risk of mechanical ventilation after bronchoalveolar lavage in patients with respiratory failure. The therapeutic approach is frequently empirical due to the fact that antibiotic therapy cannot be delayed, even for a few hours, and to the aforementioned diagnostic problems. In practice, the diagnostic and therapeutic approaches usually result from a rational compromise depending on whether the lung disease has occurred at the onset or at the end of an episode of bone marrow aplasia.
Mayaud
C
C
Centre de Pneumologie et de Réanimation respiratoire, Hôpital Tenon, Paris.
Schlemmer
B
B
Denis
M
M
Nahmias
G
G
Penaud
D
D
Akoun
G
G
D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D008171:Lung Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D009894:Opportunistic Infections / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
Les pneumopathies survenant en cours d'aplasie thérapeutique: stratégie diagnostique et thérapeutique.